The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2015 | Optimizing proteasome inhibitors for the treatment of multiple myeloma
Robert Orlowski
• 11 Apr 2015
At the Myeloma 2015 meeting, Prof Robert Orlowski (MD Anderson Cancer Center, Houston, TX) discusses multiple novel proteasome inhibitors in clinical development that have shown promising activity for the treatment of multiple myeloma. Rationally based combination therapies involving proteasome inhibitors may offer a new option to overcome drug resistance.
